Table 1.
Patient characteristics, showing mean and standard deviation or frequency and percentage
| IPAQ category | All (n = 1,270) | |||
|---|---|---|---|---|
| low (n = 138) | moderate (n = 995) | high (n = 137) | ||
| Age at study entry (years)—mean (SD) | 60.5 (12.6) | 58.6 (12.4) | 57.7 (11.9) | 58.7 (12.4) |
| BMI (kg/m2)—mean (SD) | 25.6 (5.5) | 25.9 (5.4) | 25.6 (4.7) | 25.9 (5.3) |
| Molecular tumor subtype—n (%) | ||||
| HER2pos | 26 (20.0) | 217 (23.1) | 35 (25.7) | 278 (23.1) |
| HRpos: Luminal A-like | 75 (57.7) | 425 (45.2) | 49 (36.0) | 549 (45.5) |
| HRpos: Luminal B-like | 18 (13.8) | 194 (20.6) | 32 (23.5) | 244 (20.2) |
| TNBC | 11 (8.5) | 104 (11.1) | 20 (14.7) | 135 (11.2) |
| Missing | 8 | 55 | 1 | 64 |
| Therapy line – n (%) | ||||
| 1 | 41 (29.7) | 394 (39.6) | 40 (29.2) | 475 (37.4) |
| 2 | 39 (28.3) | 241 (24.2) | 35 (25.5) | 315 (24.8) |
| 3 | 19 (13.8) | 144 (14.5) | 22 (16.1) | 185 (14.6) |
| 4 + | 39 (28.3) | 216 (21.7) | 40 (29.2) | 295 (23.2) |
| Metastasis pattern | ||||
| Brain | 12 (8.8) | 93 (9.5) | 11 (8.1) | 116 (9.3) |
| Bone | 27 (19.7) | 187 (19.1) | 23 (17.0) | 237 (18.9) |
| Visceral | 76 (55.5) | 523 (53.3) | 74 (54.8) | 673 (53.7) |
| Other | 22 (16.1) | 178 (18.1) | 27 (20.0) | 227 (18.1) |
| Missing | 1 | 14 | 2 | 17 |
| ECOG status | ||||
| 0 | 32 (32.0) | 379 (50.7) | 57 (55.9) | 468 (49.3) |
| 1 | 47 (47.0) | 316 (42.2) | 41 (40.2) | 404 (42.5) |
| 2 | 18 (18.0) | 50 (6.7) | 3 (2.9) | 71 (7.5) |
| 3 | 2 (2.0) | 3 (0.4) | 1 (1.0) | 6 (0.6) |
| 4 | 1 (1.0) | 0 (0) | 0 (0) | 1 (0.1) |
| Missing | 38 | 247 | 35 | 320 |
| Therapy | ||||
| Anti-HER2 therapy | 17 (12.3) | 180 (18.1) | 25 (18.2) | 222 (17.5) |
| Anti-hormone therapy | 15 (10.9) | 154 (15.5) | 18 (13.1) | 187 (14.7) |
| Bevacizumab | 11 (8.0) | 86 (8.6) | 12 (8.8) | 109 (8.6) |
| CDK4/6-inhibitor | 30 (21.7) | 174 (17.5) | 22 (16.1) | 226 (17.8) |
| Chemotherapy | 52 (37.7) | 337 (33.9) | 50 (36.5) | 439 (34.6) |
| mTOR-inhibitor | 7 (5.1) | 48 (4.8) | 9 (6.6) | 64 (5.0) |
| Other | 6 (4.3) | 16 (1.6) | 1 (0.7) | 23 (1.8) |
BMI Body mass index, IPAQ International Physical Activity Questionnaire, HER2 Human epidermal growth factor receptor 2, TNBC Triple negative breast cancer, ECOG Eastern Cooperative Oncology Group (ECOG) performance status, SD Standard deviation